Id |
Subject |
Object |
Predicate |
Lexical cue |
T61 |
0-8 |
Sentence |
denotes |
Table 1: |
T62 |
10-79 |
Sentence |
denotes |
Main characteristics of the 6 heart transplant patients with COVID-19 |
T63 |
80-144 |
Sentence |
denotes |
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 |
T64 |
145-157 |
Sentence |
denotes |
Demographics |
T65 |
158-194 |
Sentence |
denotes |
Age (years) 69 82 65 71 62 50 |
T66 |
195-240 |
Sentence |
denotes |
Gender Male Male Male Male Male Female |
T67 |
241-298 |
Sentence |
denotes |
Time from heart transplant (years) 5 16 11 1 22 13 |
T68 |
299-312 |
Sentence |
denotes |
Risk factors |
T69 |
313-362 |
Sentence |
denotes |
BMI (kg/m2) 22.4 23.6 24.5 25.3 32.6 21.5 |
T70 |
363-404 |
Sentence |
denotes |
Arterial hypertension − + + + + + |
T71 |
405-438 |
Sentence |
denotes |
Dyslipidaemia − + + − + − |
T72 |
439-476 |
Sentence |
denotes |
Diabetes mellitus − − − − − − |
T73 |
477-510 |
Sentence |
denotes |
Former smoker + − − − − − |
T74 |
511-556 |
Sentence |
denotes |
Extracardiac arteriopathy − − − − − − |
T75 |
557-581 |
Sentence |
denotes |
COPD − − − − − − |
T76 |
582-608 |
Sentence |
denotes |
Stroke − − − − − − |
T77 |
609-639 |
Sentence |
denotes |
Malignancy − − + − − + |
T78 |
640-678 |
Sentence |
denotes |
GFR (ml/min) 80 40 71 82 48 85 |
T79 |
679-711 |
Sentence |
denotes |
Previous PCI − + − − − − |
T80 |
712-743 |
Sentence |
denotes |
NYHA class I II I I I I |
T81 |
744-779 |
Sentence |
denotes |
Immunosuppressive therapy (mg/day) |
T82 |
780-823 |
Sentence |
denotes |
Cyclosporine 120 120 160 200 135 70 |
T83 |
824-869 |
Sentence |
denotes |
Mycophenolate 1440 − 1440 1440 1440 − |
T84 |
870-900 |
Sentence |
denotes |
Everolimus − − − − − 2 |
T85 |
901-915 |
Sentence |
denotes |
COVID-19 onset |
T86 |
916-936 |
Sentence |
denotes |
Presenting symptoms |
T87 |
937-962 |
Sentence |
denotes |
Cough + + + + + + |
T88 |
963-1002 |
Sentence |
denotes |
Shortness of breath + + + + + + |
T89 |
1003-1030 |
Sentence |
denotes |
Myalgia − + + + + + |
T90 |
1031-1058 |
Sentence |
denotes |
Anosmia − − + + + + |
T91 |
1059-1087 |
Sentence |
denotes |
Headache − − − − + + |
T92 |
1088-1117 |
Sentence |
denotes |
Sinusitis − − − − − + |
T93 |
1118-1163 |
Sentence |
denotes |
Gastrointestinal symptoms − − − − + + |
T94 |
1164-1191 |
Sentence |
denotes |
NPS test + + + + + + |
T95 |
1192-1230 |
Sentence |
denotes |
X-ray pneumonia signs + + + + − |
T96 |
1231-1283 |
Sentence |
denotes |
Fever peak (°C) 38.0 38.6 38.0 39.5 38.5 39.2 |
T97 |
1284-1318 |
Sentence |
denotes |
Hospitalization + + + + + − |
T98 |
1319-1361 |
Sentence |
denotes |
SpO2 at admission (%) 91 85 97 78 85 |
T99 |
1362-1420 |
Sentence |
denotes |
Worst SpO2 during hospitalization (%) 88 75 88 75 65 |
T100 |
1421-1453 |
Sentence |
denotes |
Laboratory results at admission |
T101 |
1454-1514 |
Sentence |
denotes |
WBC count (cells per 109/l) 10.00 9.24 4.00 7.50 5.90 |
T102 |
1515-1556 |
Sentence |
denotes |
Hb (g/dl) 10.0 13.5 12.0 13.7 13.5 |
T103 |
1557-1611 |
Sentence |
denotes |
Platelets (cells per 109/l) 400 113 215 301 151 |
T104 |
1612-1672 |
Sentence |
denotes |
Lymphocyte (cells per 109/l) 0.35 0.32 0.55 0.90 0.20 |
T105 |
1673-1709 |
Sentence |
denotes |
CRP (mg/dl) 157 140 3.3 72 29 |
T106 |
1710-1742 |
Sentence |
denotes |
PCT (ng/ml) 0.26 0.09 0 0 |
T107 |
1743-1794 |
Sentence |
denotes |
Serum creatinine (mg/dl) 1.29 2.1 1.79 1.3 2 |
T108 |
1795-1831 |
Sentence |
denotes |
Troponin I (ng/dl) 34 8 18 24 |
T109 |
1832-1861 |
Sentence |
denotes |
LVEF (%) 55 45 70 55 50 |
T110 |
1862-1884 |
Sentence |
denotes |
Treatment and outcomes |
T111 |
1885-1922 |
Sentence |
denotes |
Hydroxychloroquine + + + + + − |
T112 |
1923-1961 |
Sentence |
denotes |
Lopinavir/ritonavir + − − − + − |
T113 |
1962-2003 |
Sentence |
denotes |
Corticosteroid therapy + + + + + − |
T114 |
2004-2065 |
Sentence |
denotes |
Modification of immunosuppressive therapya + + + + + − |
T115 |
2066-2119 |
Sentence |
denotes |
% Reduction of cyclosporine 40 100 60 50 40 0 |
T116 |
2120-2171 |
Sentence |
denotes |
% Reduction of mycophenolate 75 0 0 50 50 0 |
T117 |
2172-2214 |
Sentence |
denotes |
Antibiotics prophylaxis + + + + + + |
T118 |
2215-2239 |
Sentence |
denotes |
ICU stay + − − − + |
T119 |
2240-2276 |
Sentence |
denotes |
ICU length of stay 18 − − − 2 |
T120 |
2277-2305 |
Sentence |
denotes |
High flow O2 − + − + + |
T121 |
2306-2325 |
Sentence |
denotes |
NIV − + − + + |
T122 |
2326-2352 |
Sentence |
denotes |
Intubation + − − − − |
T123 |
2353-2367 |
Sentence |
denotes |
Complications |
T124 |
2368-2399 |
Sentence |
denotes |
Respiratory − ARDS − − − |
T125 |
2400-2444 |
Sentence |
denotes |
Neurological Ischaemic stroke − − − − |
T126 |
2445-2476 |
Sentence |
denotes |
Infective Sepsis − − − − |
T127 |
2477-2524 |
Sentence |
denotes |
In-hospital length of stay 24 10 13 27 24 |
T128 |
2525-2570 |
Sentence |
denotes |
Days to negative NPS testb 10 7 15 14c |
T129 |
2571-2596 |
Sentence |
denotes |
Pronation − − − + + |
T130 |
2597-2623 |
Sentence |
denotes |
Discharged − − + + + |
T131 |
2624-2647 |
Sentence |
denotes |
Dead + + − − − − |
T132 |
2648-2730 |
Sentence |
denotes |
a In-hospital percentage reduction from last follow-up dose of immunosuppressant. |
T133 |
2731-2839 |
Sentence |
denotes |
b Days from first positive NPS test to first seriate negative NPS test and clinical resolution of symptoms. |
T134 |
2840-2989 |
Sentence |
denotes |
c The patient has been asymptomatic since receiving the results of the first NPS test, which was repeated after 14 days, per government regulations. |
T135 |
2990-3311 |
Sentence |
denotes |
ARDS: acute respiratory distress syndrome; BMI: body mass index; CRP: C-reactive protein; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; Hb: haemoglobin; ICU: intensive care unit; LVEF: left ventricular ejection fraction; NIV: non-invasive ventilation; NPS: naso-pharyngeal swab test; NYHA: |
T136 |
3312-3449 |
Sentence |
denotes |
New York heart association; PCI: percutaneous coronary intervention; PCT: procalcitonin; SpO2: oxygen saturation; WBC: white blood cells. |